

# Robert E J Ryder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9299892/publications.pdf>

Version: 2024-02-01

78  
papers

1,462  
citations

471509

17  
h-index

345221

36  
g-index

81  
all docs

81  
docs citations

81  
times ranked

1597  
citing authors

#	ARTICLE	IF	CITATIONS
1	Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service. <i>Diabetic Medicine</i> , 2022, , e14827.	2.3	4
2	FreeStyle Libre Flash Glucose Monitoring system for people with type 1 diabetes in the UK: a budget impact analysis. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002580.	2.8	6
3	Injectable semaglutide and reductions in <sc>HbA1c</sc> and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1398-1401.	4.4	8
4	The United Kingdom's first NHS EndoBarrier service for long-standing poorly controlled type 2 diabetes and obesity: outcomes one year after EndoBarrier removal. <i>British Journal of Diabetes</i> , 2021, 21, 76-83.	0.2	2
5	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. <i>British Journal of Diabetes</i> , 2021, 21, 132-148.	0.2	0
6	An audit of people admitted to hospital with diabetes and coronavirus (SARS-CoV-2): data collection methods. The Association of British Clinical Diabetologists (ABCD) Nationwide Audit. <i>British Journal of Diabetes</i> , 2021, 21, 96-99.	0.2	3
7	A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. <i>Diabetologia</i> , 2021, 64, 1717-1724.	6.3	18
8	Predictors of diabetes-related distress before and after <sc>FreeStyle Libre</sc> use: Lessons from the <sc>Association of British Clinical Diabetologists nationwide study</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2261-2268.	4.4	7
9	Impaired Awareness of Hypoglycemia and Severe Hypoglycemia in Drivers With Diabetes: Insights From the Association of British Clinical Diabetologists Nationwide Audit. <i>Diabetes Care</i> , 2021, 44, e190-e191.	8.6	3
10	Effect of Flash Glucose Monitoring on Glycemic Control, Hypoglycemia, Diabetes-Related Distress, and Resource Utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. <i>Diabetes Care</i> , 2020, 43, 2153-2160.	8.6	111
11	Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence. <i>British Journal of Diabetes</i> , 2020, 20, 28-31.	0.2	13
12	Early impact of liraglutide in routine clinical use (ABCD nationwide liraglutide audit) on cardiovascular risk (UKPDS risk engine). <i>British Journal of Diabetes</i> , 2020, 20, 25-27.	0.2	0
13	The effect of dapagliflozin on alanine aminotransferase as a marker of liver inflammation: updated results from the ABCD dapagliflozin audit. <i>British Journal of Diabetes</i> , 2020, 20, 19-24.	0.2	0
14	Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?. <i>British Journal of Diabetes</i> , 2020, 20, 5-8.	0.2	1
15	Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit. <i>British Journal of Diabetes</i> , 2020, 20, 113-116.	0.2	0
16	Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020. <i>British Journal of Diabetes</i> , 2020, 20, 85-88.	0.2	4
17	Mohammad Afzal Mir. <i>BMJ: British Medical Journal</i> , 2019, , 14841.	2.3	0
18	Pioglitazone: inexpensive; very effective at reducing HbA 1c ; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit. <i>Diabetic Medicine</i> , 2019, 36, 1185-1186.	2.3	6

#	ARTICLE	IF	CITATIONS
19	The United Kingdom's first NHS Endobarrier service for advanced diabetes: 1-year outcomes for all 62 treated patients. <i>British Journal of Diabetes</i> , 2019, 19, 110-117.	0.2	8
20	Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 receptor agonists complement each other to save lives by different mechanisms?. <i>British Journal of Diabetes</i> , 2019, 19, 1-5.	0.2	4
21	Reductions in alanine aminotransferase levels with liraglutide treatment are greatest in those with raised baseline levels and are independent of weight loss: real-world outcome data from the ABCD Nationwide Liraglutide Audit. <i>British Journal of Diabetes</i> , 2019, 19, 118-123.	0.2	0
22	Real-world diabetes prevention: from theory to practice. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 756-757.	11.4	3
23	Maintenance of efficacy after duodenal " jejunal bypass liner explantation in the first NHS EndoBarrier service. <i>British Journal of Diabetes</i> , 2018, 18, 14-17.	0.2	1
24	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017, 40, 813-820.	8.6	109
25	Retinal vessel diameters and reactivity in diabetes mellitus and/or cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2017, 16, 56.	6.8	28
26	OC-001...Efficacy, safety and tolerability outcomes of endoscopic proximal intestinal exclusion using endobarrier, 12 and 18 month data for the UK's first NHS endobarrier service for diabetes. , 2017, , .		0
27	Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?. <i>British Journal of Diabetes</i> , 2017, 17, 131-133.	0.2	6
28	What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?. <i>British Journal of Diabetes</i> , 2017, 17, 89.	0.2	2
29	951 Endoscopic Proximal Intestinal Exclusion Can Improve Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients With Diabetes. <i>Gastroenterology</i> , 2016, 150, S1055-S1056.	1.3	2
30	Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter 2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 454-462.	4.4	44
31	This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes. <i>British Journal of Diabetes</i> , 2016, 16, 88.	0.2	0
32	Clinical use of Humulin R U-500 insulin in the UK: results of the first Association of British Clinical Diabetologists' U-500 audit. <i>British Journal of Diabetes</i> , 2016, 16, 185.	0.2	1
33	Diabetes medications with cardiovascular protection " what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?. <i>British Journal of Diabetes</i> , 2016, 16, 103.	0.2	6
34	Bariatric surgery and surgical devices in obesity management. <i>British Journal of Diabetes</i> , 2016, 16, 156.	0.2	0
35	Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. <i>Diabetic Medicine</i> , 2015, 32, 438-439.	2.3	7
36	The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 124-129.	2.8	19

#	ARTICLE	IF	CITATIONS
37	Pioglitazone: reports of its death are greatly exaggerated – it is alive and ready to resume saving lives. Diabetic Medicine, 2015, 32, e9-e15.	2.3	6
38	Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit. Diabetic Medicine, 2015, 32, 305-313.	2.3	35
39	Rehabilitation of pioglitazone. British Journal of Diabetes and Vascular Disease, 2015, 15, 46.	0.6	9
40	Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin. British Journal of Diabetes and Vascular Disease, 2015, 15, 151.	0.6	10
41	Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit. British Journal of Diabetes and Vascular Disease, 2015, 15, 169.	0.6	6
42	Inpatient diabetes: do-it-yourself electronic referral system to support and enhance the Think Glucose project. Practical Diabetes, 2014, 31, 194-196.	0.3	5
43	The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multicentre observational study. Diabetic Medicine, 2014, 31, 403-411.	2.3	18
44	GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice. British Journal of Diabetes and Vascular Disease, 2014, 14, 52.	0.6	25
45	ABCD now on N3: The ABCD nationwide exenatide QW audit. British Journal of Diabetes and Vascular Disease, 2014, 14, 40.	0.6	0
46	Safety and efficacy of liraglutide 1.2mg in patients with mild and moderate renal impairment: the ABCD nationwide liraglutide audit. Practical Diabetes, 2013, 30, 71.	0.3	13
47	The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis – what happens next? A personal viewpoint. Diabetic Medicine, 2013, 30, 1510-1511.	2.3	3
48	Was it really pancreatitis from GLP-1 receptor agonist therapy?. Practical Diabetes, 2013, 30, 310-310.	0.3	0
49	ABCD position statement on GLP-1 based therapies and pancreatic damage. Practical Diabetes, 2013, 30, 388-391.	0.3	1
50	The potential risks of pancreatitis and pancreatic cancer with GLP-1 based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabetic Medicine, 2013, 30, 1148-1155.	2.3	32
51	Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide-1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits. Diabetic Medicine, 2012, 29, 690-692.	2.3	6
52	An automated retinal image quality grading algorithm. , 2011, 2011, 5955-8.		22
53	Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Research and Clinical Practice, 2011, 93, e87-e91.	2.8	18
54	Pioglitazone and bladder cancer. Lancet, The, 2011, 378, 1544.	13.7	8

#	ARTICLE	IF	CITATIONS
55	Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes, Obesity and Metabolism, 2011, 13, 703-710.	4.4	83
56	Automated diagnosis of referable maculopathy in diabetic retinopathy screening. , 2011, 2011, 3375-8.		21
57	Nontraumatic rhabdomyolysis: an unusual complication of diabetic hyperosmolar nonketotic (HONK) state. Journal of the Royal Society of Medicine, 2006, 99, 200-200.	2.0	13
58	Uncommon presentation of asymmetrical retinopathy in diabetes type 1. Acta Ophthalmologica, 2004, 82, 321-323.	0.3	1
59	New Treatment Options for Erectile Dysfunction in Patients with Diabetes Mellitus. Drugs, 2004, 64, 2667-2688.	10.9	86
60	Diagnosis of Adrenal Insufficiency. Annals of Internal Medicine, 2003, 139, 194.	3.9	266
61	Impotence in Diabetes. Trends in Endocrinology and Metabolism, 1997, 8, 98-101.	7.1	5
62	Impotence in diabetes mellitus. Diabetes/metabolism Reviews, 1995, 11, 279-285.	0.3	18
63	ACE inhibitors and hypoglycaemia. Lancet, The, 1995, 346, 125-127.	13.7	5
64	"Natural family planning": effective birth control supported by the Catholic Church.. BMJ: British Medical Journal, 1993, 307, 723-726.	2.3	82
65	Natural family planning. Author's reply.. BMJ: British Medical Journal, 1993, 307, 1360-1360.	2.3	2
66	Detecting diabetic retinopathy.. BMJ: British Medical Journal, 1991, 302, 659-659.	2.3	0
67	Pulmonary Embolism Masquerading as Stokes-Adams Attacks. Journal of the Royal Society of Medicine, 1987, 80, 460-461.	2.0	2
68	The metabolic response to glucagon and glucagonâ€“(1â€“(21)â€“(peptide in normal subjects and non insulin dependent diabetics.. British Journal of Clinical Pharmacology, 1986, 22, 325-329.	2.4	2
69	Ovarian ultrasonography highlights precision of symptoms of ovulation as markers of ovulation.. BMJ: British Medical Journal, 1986, 292, 1562-1562.	2.3	15
70	Screening for diabetic retinopathy. BMJ: British Medical Journal, 1985, 290, 1349-1349.	2.3	1
71	Lactic Acidosis: High-Dose or Low-Dose Bicarbonate Therapy?. Diabetes Care, 1984, 7, 99-102.	8.6	23
72	Bicarbonate Therapy and Lactic Acidosis: A Reply. Diabetes Care, 1984, 7, 510-510.	8.6	2

#	ARTICLE	IF	CITATIONS
73	Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. British Journal of Clinical Pharmacology, 1983, 16, 185-187.	2.4	104
74	Glycosylated Serum Albumin: An Intermediate Index of Diabetic Control. Diabetes Care, 1983, 6, 501-503.	8.6	77
75	Normo-osmolar, Nonketotic, Hyponatremic Diabetic Syndrome Associated with Impaired Renal Function. Diabetes Care, 1983, 6, 402-404.	8.6	10
76	Previous structured education attendance and the relationship with HbA1c and hypoglycaemia awareness in people living with type 1 diabetes mellitus using FreeStyle Libre: insights from the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. British Journal of Diabetes, 0, , .	0.2	0
77	The effect of sodium-glucose link transporter 2 inhibitors on heart failure end points in people with type 2 diabetes mellitus: a systematic review and meta-analysis. British Journal of Diabetes, 0, , .	0.2	1
78	COVID-19 outcomes in people with diabetes in Wales: a secondary analysis of the ABCD audit. British Journal of Diabetes, 0, , .	0.2	0